Special Issue

Musculoskeletal Regenerative Medicine

Message from the Guest Editors

Over the last decade, there has been an increasing interest in the use of biologics for regenerative medicine applications. In regenerative medicine, functional tissue is engineered to repair, regenerate, or replace cells, tissues, or organs to restore and/or establish normal function lost from age, disease, damage, or congenital defects. Both autologous and allogenic biologics are currently used in clinical practice. Autologous biologics include platelet-rich plasma, bone marrow aspirate/concentrate, and adipose tissue aspirate. Allogenic biologics include formulations derived from perinatal tissues, including amniotic fluid, amniotic membrane, umbilical cord, and umbilical cord blood. The healing potential of these products is attributed to the presence of stem cells, growth factors, cytokines, hyaluronic acid, and extracellular vesicles, including exosomes.

Guest Editors

Dr. Ashim Gupta

1. Future Biologics, Lawrenceville, GA, USA
2. South Texas Orthopaedic Research Institute (STORI Inc.), Laredo, TX, USA

Prof. Dr. Nicola Maffulli

1. Department of Trauma and Orthopaedics, Sapienza University, Roma, Italy
2. Barts and The London School of Medicine and Dentistry, Mile End Hospital, Queen Mary University of London, 275 Bancroft Road, London E1 4DG, UK
3. School of Pharmacy and Bioengineering, Keele University Faculty of Medicine, Thornburrow Drive, Stoke on Trent ST4 7QB, UK

Deadline for manuscript submissions

closed (31 August 2024)

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/si/184939

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/journal/biomedicines

About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni
1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).